Warning Letter Record: Amazon.com, Inc. (2026-10-01) — Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
In short: On October 1, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Amazon.com, Inc. (CEO Andy Jassy) identifying nine products sold through amazon.com as unapproved new drugs: FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula, and Genital Herpes Intimate Wash. The FDA determined these products violate the Federal Food, Drug, and Cosmetic Act sections 301(d) and 505(a) because their labeling claims—including symptom relief, outbreak reduction, and anti-fungal/anti-microbial purposes—establish intended use as drugs for treating sexually transmitted infections without FDA approval. The FDA noted that unapproved STI treatments present a serious public health concern, as consumers may forgo appropriate medical care and unknowingly transmit infections to partners.
Argus analysis
# FDA Warning Letter Analysis: Amazon.com, Inc. — Unapproved STI Drug Products
Amazon.com, Inc. received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026, regarding nine unapproved drug products sold through its marketplace and Fulfillment by Amazon service. The products—including FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula, and Genital Herpes Intimate Wash—were marketed for treating genital herpes and other sexually transmitted infections. The FDA identified these products during a July 2026 review of labeling purchased directly from Amazon's website.
The violations center on sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act, which require FDA approval before marketing new drugs. The products qualify as drugs under 21 CFR 201.128 (intended use definition) because their labeling contains claims such as "fast-acting outbreak symptom relief," "reduces viral activity," and promises to relieve itching, burning, and pain associated with genital herpes. The FDA emphasizes that no over-the-counter drug has been approved for treating any STI, and homeopathic products (like Terragen HG Formula) receive no exemption from approval requirements, despite being listed in the Homeopathic Pharmacopeia.
Amazon must submit a written response within 15 business days to FDAAdvisory@fda.hhs.gov describing corrective actions and preventative measures. Compliance officers should monitor whether Amazon implements enhanced product screening for STI-related claims, removes the flagged products, or pursues supplier accountability measures. The warning letter signals FDA's intensified focus on marketplace platforms distributing unapproved drugs; similar enforcement actions may follow against other e-commerce retailers and third-party sellers.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Amazon.com, Inc. MARCS-CMS 736006 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Andy Jassy Recipient Title CEO Amazon.com, Inc. P.O. Box 81226 Seattle , WA 98108-1226 United States (b)(6) Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 736006 To Andy Jassy: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of drug products that were purchased on your website, www.amazon.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “FemiClear,” “Hclear for him,” “HerpCare Ointment,” “HerpCare Spray,” “Herstat GST,” “Genital Herpes Ointment,” “RoyceDerm Herpes Relief Cream,” “Terragen HG Formula,” and “Genital Herpes Intimate Wash” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during review of the product labeling of products purchased on your website www.amazon.com in July 2026. FDA purchased, “FemiClear,” “HClear for him,” “HerpCare Ointment,” “HerpCare Spray,” “Herstat GST,” “Genital Herpes Ointment,” “RoyceDerm Herpes Relief Cream,” “Terragen HG Formula,” and “Genital Herpes Intimate Wash” through your website and these products were introduced or delivered for introduction into interstate commerce by Amazon via your Fulfillment by Amazon service. 1 Based on our review, “FemiClear,” “HClear for him,” “HerpCare Ointment,” “HerpCare Spr…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Other FDA letters on Amazon.com, Inc.
- Amazon.com, Inc. — Unapproved New Drugs/Misbranded (2026-06-17)
2026-06-17 · critical
Frequently asked questions
- Is the FDA warning letter to Amazon.com, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazoncom-inc-736006-10012026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Amazon.com, Inc. (2026-10-01) — Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-amazon-com-inc-2026-10-01-unapproved-drug
"Warning Letter Record: Amazon.com, Inc. (2026-10-01) — Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-amazon-com-inc-2026-10-01-unapproved-drug.
Argus HQ Research. "Warning Letter Record: Amazon.com, Inc. (2026-10-01) — Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 8, 2026. https://argushq.ai/fda/warning-letter/fda-wl-amazon-com-inc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_amazon_com_inc_2026_10_01_unapproved_drug_2026,
title = {Warning Letter Record: Amazon.com, Inc. (2026-10-01) — Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-amazon-com-inc-2026-10-01-unapproved-drug},
note = {Accessed: October 8, 2026}
}